Inhibition of intestinal farnesoid X receptor-sphingomyelin phosphodiesterase 3-axis new mechanism to reduce atherosclerosis

On May 3, Jiang Changtao’s research team from Peking University School of Basic Medicine published a research paper entitled "Suppressing the intestinal farnesoid X receptor-sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis" online in The Journal of Clinical Investigation, which systematically reported Intestinal FXR plays an important role in the occurrence and development of atherosclerosis

Intestinal farnesoid X receptor (FXR) is a nuclear receptor with bile acid as its natural ligand.

Mechanism studies have shown that the lack of intestinal FXR on the one hand accelerates cholesterol catabolism mediated by cholesterol 7α hydroxylase (CYP7A1) in the liver by inhibiting the secretion of intestinal FGF19, and on the other hand, it inhibits ceramide bypass synthesis of the key enzyme-sphingomyelin phosphodiester.

The study found that the intestinal FXR-SMPD3 axis is expected to become a new intervention target for the treatment of atherosclerotic diseases, and provides the intestinal FXR-specific endogenous antagonist glycyursodeoxycholic acid GUDCA and SMPD3 inhibitor GW4869 can be used for arteriosclerosis Strong evidence for disease treatment

Researcher Jiang Changtao, School of Basic Medical Sciences, Peking University School of Medicine, Researcher Frank J.

Original link:

Suppressing the intestinal farnesoid X receptor-sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis

https://